Details for Patent: 5,635,517
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 5,635,517
Title: | Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Abstract: | 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline. |
Inventor(s): | Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger S. -C. (Edison, NJ) |
Assignee: | Celgene Corporation (Warren, NJ) |
Application Number: | 08/690,258 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 5,635,517 |
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 5,635,517
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,635,517
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 229521 | See Plans and Pricing | |||
Austria | 275139 | See Plans and Pricing | |||
Austria | 401319 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |